ELK1 and melanoma: As expected, EMSA demonstrated the enhanced DNA‐binding activity of the different transcription factors AP‐1 (Fig. 3C and D), ATF‐2 (Fig. 3E and F), p53 (Fig. 3G and H) and ELK‐1 (Fig. 3I and J) in both melanoma cell lines BLM and MV3 upon imiquimod treatment.